Treatment of meiob stage lib amyloidosis
By using monoclonal antibodies with specific amino acid sequences and standard care protocols, treatment of Mayo Clinic stage IIIb light chain amyloidosis significantly improved patients' clinical symptoms and cardiac function, addressing the lack of effective treatments in existing technologies.
Patent Information
- Application Number
- CN202580021413.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-15
- Filing Date
- 2025-03-14
- Publication Date
- 2026-11-10
AI Technical Summary
There is a lack of effective treatments for Mayo Clinic stage IIIb light chain amyloidosis, especially for the targeting and clearance of amyloid protein deposits.
Monoclonal antibodies with specific amino acid sequences, including heavy chain variable domains (VH) and light chain variable domains (VL), combined with the standard care regimen of cyclophosphamide, bortezomib, and dexamethasone (CyBorD), are used to treat patients with Mayo Clinic stage IIIb light chain amyloidosis to reduce amyloid deposits.
After 50 weeks of treatment, patients showed significant improvements in the Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS), Global Longitudinal Strain (GLS%) cardiac improvement, Six-Minute Walk Test (6MWT) scores, and Short Form-36 (SF-36) v2 Physical Health Score (PCS).
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Background Technology
[0001] Amyloidosis, or amyloid protein disease, is a rare condition that occurs when amyloid proteins accumulate in organs and interfere with their normal function. Amyloid proteins are not normally present in the body, but they can be formed from several different types of proteins. Organs that may be affected include the heart, kidneys, liver, spleen, nervous system, skin, and digestive tract. Amyloid light chain amyloidosis (AL amyloidosis, AL, or ALA), also known as primary amyloidosis, is the most common form of systemic amyloidosis in the United States and accounts for approximately 70% of amyloidosis cases diagnosed in developed countries. However, the term "amyloidosis" refers to a group of diseases with a common characteristic: the extracellular deposition of pathological, insoluble fibrillary proteins in organs and tissues. AL amyloidosis is caused by dysfunction of antibody-producing cells, which leads to the production of abnormal protein fibers that aggregate in organs and tissues to form insoluble amyloid deposits. In primary amyloidosis, protofibrils consist of complete segments or fragments of immunoglobulin light chains, while in secondary amyloidosis, protofibrils consist of amyloid A protein. Modern classification of amyloidosis is based on the nature of the precursor plasma proteins that form protofibril deposits.
[0002] The therapeutic targeting and clearance of amyloid deposits is an area of great medical interest, as there are still no approved therapies, representing a significant unmet medical need. Summary of the Invention
[0003] This disclosure relates to a method for treating subjects with Mayo Clinic stage IIIb light chain (AL) amyloidosis.
[0004] In one aspect, this disclosure is characterized by a method for reducing the amount of amyloid deposits in a subject suffering from Mayo Clinic stage IIIb light chain (AL) amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby reducing the amount of amyloid deposits in the subject.
[0005] On the other hand, this disclosure is characterized by a method for treating a subject with Mayo Clinic stage IIIb AL amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby treating the Mayo Clinic stage IIIb AL amyloidosis.
[0006] In some embodiments, subjects were administered a cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen in accordance with institutional standard care.
[0007] In some embodiments, each administration comprises about 300 mg of an antibody having a heavy chain variable domain (VH) with the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) with the amino acid sequence SEQ ID NO:2.
[0008] In some embodiments, subjects are administered antibodies or receive treatment for at least 50 weeks.
[0009] In some embodiments, after 50 weeks of treatment, subjects achieved a statistically significant improvement in their Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS) relative to baseline.
[0010] In some embodiments, after 50 weeks of treatment, subjects achieved a statistically significant improvement in their cardiac improvement score based on global longitudinal strain (GLS%) relative to baseline.
[0011] In some embodiments, after 50 weeks of treatment, subjects achieved a statistically significant improvement in walking distance during the six-minute walk test (6MWT) relative to baseline.
[0012] In some embodiments, after 50 weeks of treatment, subjects achieved statistically significant improvement in their Short Form-36 (SF-36) v2 Physical Health Score (PCS) relative to baseline. Detailed Implementation
[0013] The study aimed to evaluate the efficacy and safety of antibody 1 in patients with Mayo Clinic stage IIIb light chain (AL) amyloidosis.
[0014] A phase 3, double-blind, multicenter study was conducted to evaluate the efficacy and safety of antibody 1 and plasma cell cachexia treatment compared with placebo and plasma cell cachexia treatment in patients with Mayo Clinic stage IIIb AL amyloidosis who were previously untreated for plasma cell cachexia.
[0015] AL (or light chain) amyloidosis begins in the bone marrow, where abnormal proteins misfold and produce free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils, which accumulate in the extracellular spaces of organs, affecting the kidneys, heart, liver, spleen, nervous system, and digestive tract.
[0016] The primary objective of this study was to determine whether antibody 1 (a monoclonal antibody that clears AL amyloid deposits from tissues and organs) improves overall survival in patients with stage IIIb AL amyloidosis, and whether the antibody is safe and well-tolerated in these patients.
[0017] The disclosed antibody is used to treat amyloidosis and related disorders. Typically, the antibody consists of four polypeptides: two identical copies of the heavy (H) chain polypeptide and two copies of the light (L) chain polypeptide. There are five types of heavy chains: IgG, IgM, IgA, IgD, or IgE; and two possible types of light chains: κ (kappa) or λ (lambda). Each heavy chain contains one N-terminal variable (VH) region and three C-terminal constant (CH1, CH2, and CH3) regions, and each light chain contains one N-terminal variable (VL or VK, or V... λ or V κ The antibody consists of a C-terminal variable domain and a C-terminal constant (CL) region. Each variable domain of the light and heavy chains also includes three segments called complementarity-determining regions (“CDRs”) or hypervariable regions. Each CDR in the light chain, together with its corresponding CDR in the adjacent heavy chain, forms the antibody's antigen-binding site. The variable regions of each pair of light and heavy chains form the antibody's antigen-binding site, while the constant regions provide structural support and regulate the immune response triggered by antigen binding.
[0018] Antibody 1 has a VL region (SEQ ID NO:2) and a VH region (SEQ ID NO:1), as shown in Table 1 below. The CDR sequences of the heavy and light chains of antibody 1 are provided in Table 2 below. Antibody 1 is also described in PCT international application PCT / US2021 / 050316, published as WO 2022 / 056484, and the description of antibody 1 is hereby incorporated by reference.
[0019] Table 1: Alternative sequences of monoclonal antibodies
[0020]
[0021] Table 2: CDR sequences of monoclonal antibodies
[0022]
[0023] This is a double-blind, randomized, multicenter international phase 3 study comparing antibody-1 in treatment-naïve patients with stage IIIb plasma cell cachexia (PCD) with standard of care (SoC) PCD versus placebo in combination with SoC PCD. As this is an event-driven study, enrollment will continue until at least 101 deaths are observed. Approximately 124 patients are planned to be enrolled using a 2:1 randomization ratio. Stratification is based on the geographic region of the research center. An interim analysis (IA) can be performed when approximately 75% (76 / 101) of expected deaths are observed. Patients in both intervention groups will be followed from randomization until death from any cause or until the end of the study.
[0024] Plan Description
[0025] Each patient is assigned a unique identifier after signing the informed consent form (ICF).
[0026] Research Design
[0027] This study is an interventional study with a primary objective of treatment. It is a phase 3 study. The intervention study model is a parallel allocation. There are two groups, and the allocation is randomized. Blinding includes participants, care providers, researchers, and outcome assessors. The blinding is described as follows: This is a double-blind, randomized, multicenter international phase 3 study. The target enrollment is 124 participants.
[0028] Model Description
[0029] This is a double-blind, randomized, multicenter international phase 3 study comparing antibody-based therapy in combination with SoCPCD versus placebo in treatment-naïve patients with stage IIIb PCD-naïve AL amyloidosis at the Mayo Clinic. As this is an event-driven study, enrollment will continue until at least 101 deaths are observed. Approximately 124 patients are planned to be enrolled using a 2:1 randomization ratio, with stratification based on the geographic region of the research center. An interim analysis (IA) with early efficacy cessation rules can be performed when approximately 75% (76 / 101) of expected deaths are observed. Patients in both intervention groups will be followed from randomization until death from any cause or until the end of the study.
[0030] Intervention
[0031] Group
[0032] The number of groups is 2, as follows:
[0033] Group 1
[0034] Group title: Antibody 1 combined with SoC plasma cell cachexia.
[0035] Group type: Experimental
[0036] Group Description: Antibody 1 was administered via intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment duration for each patient was at least 50 weeks or until death. All patients were planned to continue double-blind treatment until the last patient completed at least 50 weeks of treatment. The study was divided into two phases: a primary assessment treatment phase and an open-label extension study phase.
[0037] Group 2
[0038] Group title: Placebo combined with SoC plasma cell cachexia.
[0039] Group type: placebo control
[0040] Group Description: Patients randomized to receive placebo were administered an equal volume (approximately 250 cc) of 0.9% saline solution to antibody 1. The minimum planned treatment duration for each patient was at least 50 weeks or until death. All patients were planned to continue double-blind treatment until the last patient completed at least 50 weeks of treatment.
[0041] Intervention
[0042] Table 3:
[0043]
[0044] Outcome Indicators
[0045] Key outcome indicators
[0046] Table 4:
[0047]
[0048] Secondary outcome indicators
[0049] Table 5:
[0050]
[0051] qualifications
[0052] The study included all patients. This study is not based on gender. The minimum age requirement is 18 years old; there is no maximum age limit. Healthy volunteers are not eligible. Eligibility criteria are as follows:
[0053] Key selection criteria:
[0054] At the time of screening, the patient had stage IIIb AL amyloidosis (NT-proBNP > 8,500 ng / L) based on the 2004 Mayo Clinic Stages European Modified.
[0055] At the time of screening, the individual must have a measurable blood disorder, as defined by at least one of the following:
[0056] a. Difference in affected / unaffected free light chains (dFLC) > 4 mg / dL, or
[0057] b. Affected free light chains (iFLC) > 4 mg / dL and abnormal κ / λ ratio, or
[0058] c. Serum protein electrophoresis (SPEP) m peak > 0.5 g / dL.
[0059] Based on polarized light microscopy using green birefringent material in Congo red-stained tissue samples, the histopathological diagnosis is amyloidosis, and the deposition of AL-derived amyloid protein is confirmed by at least one of the following:
[0060] a. Immunohistochemistry / immunofluorescence, or
[0061] b. Mass spectrometry, or
[0062] c. Characteristic electron microscopic features / immunoelectron microscopy.
[0063] Cardiac involvement, as defined below:
[0064] a. In the absence of an alternative explanation for heart failure, and in the context of a confirmed diagnosis of AL amyloidosis, documented clinical signs and symptoms that support the diagnosis of heart failure.
[0065] as well as
[0066] b. At least one of the following:
[0067] i. Endocardial biopsy showing AL cardiac amyloidosis, or
[0068] ii. In the absence of other causes (e.g., severe hypertension, aortic stenosis), echocardiography showing a mean left ventricular wall thickness (calculated as [IVSd+LPWd] / 2) > 12 mm during diastole would adequately explain the degree of wall thickening, or
[0069] iii. Cardiac magnetic resonance imaging (MRI) and gadolinium contrast agents for the diagnosis of cardiac amyloidosis.
[0070] The planned first-line treatment for plasma cell cachexia is a cyclophosphamide-bortezomib-dexamethasone (CyBorD) regimen administered as a SoC.
[0071] Women of childbearing potential (WOCBP) must have a negative pregnancy test during the screening period and must agree to use highly effective contraception from screening until at least 5 months after the last administration of the study drug or 12 months after the last dose of their PCD therapy (whichever is longer).
[0072] Men must be surgically infertile or must agree to use highly effective contraception and avoid donating sperm for at least 5 months from screening to the last administration of the study drug or 12 months after the last dose of their PCD therapy (whichever is longer).
[0073] Key exclusion criteria:
[0074] Having any other form of amyloidosis besides AL amyloidosis.
[0075] Prior therapy for AL amyloidosis or multiple myeloma. Maximum exposure to CyBorD-based PCD treatment for 2 weeks after obtaining screening laboratory samples and before being allowed randomization.
[0076] Patients with POEMS (plasma cell cachexia with polyneuropathy, organomegaly, endocrine disorders, monoclonal protein and skin changes) syndrome, or multiple myeloma defined as having >10% clonal bone marrow plasma cells based on bone marrow biopsy (performed ≤ 3 months prior to ICF signing), or biopsy-confirmed bone or extramedullary plasmacytoma (performed ≤ 3 months prior to ICF signing), and one or more of the following CRAB features:
[0077] a. Evidence of end-organ damage that can be attributed to underlying plasma cell proliferation disorders (e.g., multiple myeloma and POEMS syndrome), specifically:
[0078] i. Hypercalcemia: Serum calcium levels above the ULN > 0.25 mmol / L (> 1 mg / dL) or > 2.75 mmol / L (> 11 mg / dL), or
[0079] ii. Renal insufficiency: creatinine clearance < 40 mL / min or serum creatinine > 177 mol / L (> 2 mg / dL), or
[0080] iii. Anemia: Hemoglobin level below the lower limit of normal > 20 g / L, or hemoglobin level < 100 g / L, or
[0081] iv. Bone lesions: One or more osteolytic lesions in imaging tests (performed ≤ 3 months prior to ICF signing): bone radiography, CT, or PET / CT or MRI. If the bone marrow has < 10% clonal plasma cells, more than one bone lesion is required to differentiate it from solitary plasmacytoma with minimal bone marrow involvement, or
[0082] b. Any one of the following biomarkers for malignant tumors:
[0083] i. 60% or more clonal plasma cells in bone marrow examination, or
[0084] ii. More than one focal lesion measuring at least 5 mm or larger on MRI.
[0085] Supine systolic blood pressure < 90 mmHg or symptomatic orthostatic hypotension is defined as a decrease in systolic blood pressure > 30 mmHg when standing, despite medical management (e.g., midodrine, fludrocortisone) without loss of blood volume.
[0086] Numbered Examples
[0087] 1. A method for reducing the amount of amyloid deposits in a subject with Mayo Clinic stage IIIb light chain (AL) amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby reducing the amount of amyloid deposits in the subject.
[0088] 2. A method for treating a subject with Mayo Clinic stage IIIb AL amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby treating the Mayo Clinic stage IIIb AL amyloidosis.
[0089] 3. The method as described in Example 1 or 2, wherein the subject is administered the antibody or receives treatment for at least 50 weeks.
[0090] 4. The method as described in any one of Examples 1-3, wherein after 50 weeks of treatment, the subject’s Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS) shows a statistically significant improvement relative to baseline.
[0091] 5. The method as described in any one of Examples 1-3, wherein after 50 weeks of treatment, the subject’s cardiac improvement score based on global longitudinal strain (GLS%) achieved a statistically significant improvement relative to baseline.
[0092] 6. The method as described in any one of Examples 1-3, wherein after 50 weeks of treatment, the subject achieved a statistically significant improvement in walking distance during the six-minute walk test (6MWT) relative to baseline.
[0093] 7. The method as described in any one of Examples 1-3, wherein after 50 weeks of treatment, the subject’s Short Form-36 (SF-36) v2 Physical Health Score (PCS) shows a statistically significant improvement relative to baseline.
[0094] Other embodiments
[0095] All references cited in this specification (including database entries (e.g., in GENBANK, UNIPROT, PUBMED)) are incorporated herein by reference as each reference specifically and individually indicates its inclusion by reference. Any citation of a reference is for disclosure prior to the submission date and should not be construed as an admission that this disclosure is not prior to such references due to prior invention.
[0096] It will be understood that each, or two or more, of the foregoing elements can also find useful applications in other types of methods different from those described above. Without further analysis, the foregoing so fully reveals the essential points of this disclosure that others can easily modify it for various applications by applying existing knowledge, without omitting features that, from the viewpoint of the prior art, clearly constitute the general or specific aspects of this disclosure set forth in the appended claims. The foregoing embodiments are given by way of example only.
Claims
1. A method for reducing the amount of amyloid deposits in a subject with Mayo Clinic stage IIIb light chain (AL) amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby reducing the amount of amyloid deposits in the subject.
2. A method for treating a subject with Mayo Clinic stage IIIb AL amyloidosis, the method comprising administering to the subject an effective amount of an antibody having a heavy chain variable domain (VH) of the amino acid sequence SEQ ID NO:1 and a light chain variable domain (VL) of the amino acid sequence SEQ ID NO:2, thereby treating the Mayo Clinic stage IIIb AL amyloidosis.
3. The method of claim 1 or 2, wherein the subject is administered the antibody or receives treatment for at least 50 weeks.
4. The method of claim 1 or 2, wherein after 50 weeks of treatment, the subject’s Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS) shows a statistically significant improvement relative to baseline.
5. The method of claim 1 or 2, wherein after 50 weeks of treatment, the subject’s cardiac improvement score based on global longitudinal strain (GLS%) achieved a statistically significant improvement relative to baseline.
6. The method of claim 1 or 2, wherein after 50 weeks of treatment, the subject achieved a statistically significant improvement in walking distance during the six-minute walk test (6MWT) relative to baseline.
7. The method of claim 1 or 2, wherein after 50 weeks of treatment, the subject’s Short Form-36 (SF-36) v2 Physical Health Score (PCS) shows a statistically significant improvement relative to baseline.
Citation Information
Patent Citations
Method of treating amyloidosis
WO2022056484A1
